StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)

Close on Nov 17, 2026Market cap $6.07BP/E –Yield –

Arrowhead Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Arrowhead Pharmaceuticals's price to sales ratio was 10.4× on Nov 11, 2026, against 8.6× a year earlier. Over the last 5 years it ranged from 4.0× to 150.7×, with a median of 14.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202610.4×−0.5
2025Dec 31, 202510.9×−110.7
2024Oct 31, 2024121.6×+107.9
2023Dec 29, 202313.6×−4.0
2022Dec 30, 202217.7×−32.3
2021Dec 31, 202150.0×−39.3
2020Dec 31, 202089.3×+53.4
2019Dec 31, 201935.9×−32.2
2018Dec 31, 201868.1×+59.3
2017Dec 29, 20178.8×−428.7
2013Jul 31, 2013437.5×+239.6
2012Dec 31, 2012197.8×+75.6
2011Dec 30, 2011122.3×–

More Arrowhead Pharmaceuticals figures

See a number that looks wrong?